Pharmascience Inc. launches (Pr)pms-PROGESTERONE 200 mg capsule indicated as an adjunct to postmenopausal estrogen replacement therapy
MONTREAL, March, 29, 2019 /CNW Telbec/ - Pharmascience Inc. is proud to launch Prpms-PROGESTERONE 200 mg (progestin), the only 200 mg progestin capsule available in Canada for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to significantly reduce the risk of endometrial hyperplasia and carcinoma. 1
Menopause is a process that takes place over several years and usually begins in the early 50s. Studies show that estrogens, commonly prescribed in menopause, maintain the woman's bone structure and prevent fractures caused by osteoporosis as well as help relieve the symptoms associated with their condition. Progesterone can be added to estrogen replacement therapy to avoid stimulation of the inner lining of the uterus and its cancer. 2
"We are very proud to launch this innovative format. Having Prpms-PROGESTERONE 200 mg capsules will greatly enhance patient convenience. We are committed to women's health and look forward to further innovation and increased presence in this very important segment." said Al Moghaddam, Vice-President, Sales and Marketing at Pharmascience Canada.
Each coated Prpms-PROGESTERONE capsule contains 200 mg of micronized progesterone in addition to several non-medicinal ingredients including sunflower oil. 1
About Pharmascience Inc.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 56th among Canada's top 100 Research & Development (R&D) investors with over $43 million invested in 2018, Pharmascience Inc. is the 4th largest manufacturer of over-the-counter generic drugs in the country.
Pharmascience Inc. is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. The company commercializes nearly 300 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.
In 2018, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as a partner of choice to increase access to medicine. Pharmascience's total donations of essential medicine is close to $70 million.
For more information, please visit www.pharmascience.com.
References: 1. Prpms-PROGESTERONE product monograph. Pharmascience Inc. August 20, 2018. 2. Association des obstétriciens et gynécologues du Québec http://www.gynecoquebec.com/. Consulted: March 27, 2019.
SOURCE Pharmascience Inc.
For further information:
For all media requests, Valérie Piuze, Communications Manager, Tel: 514-340-9800, ext. 7846, mediainquiries@pharmascience.com
